https://doi.org/10.55788/5470b753
“Although intensive frontline therapies can deliver durable responses in patients with MCL, these treatments are not suited for older patients due to poor tolerability,” elaborated Prof. Michael Wang (University of Texas, TX, USA) [1]. Thus, BR is therefore the most frequently administered first-line therapy in this population. Recently, the addition of the BTK inhibitor acalabrutinib to BR delivered promising safety and efficacy results in a phase 1 study (NCT02717624) [2].
To further evaluate this combination therapy, the current phase 3 ECHO trial (NCT02972840) randomised 598 participants over 64 years of age with newly diagnosed MCL 1:1 to BR plus acalabrutinib or BR plus placebo. The primary endpoint was progression-free survival (PFS). “Participants in the placebo arm were permitted to cross over to acalabrutinib if they had disease progression,” noted Prof. Wang.
After a median follow-up of 45 months, PFS was improved in the acalabrutinib arm compared with the placebo arm (HR 0.73; 95% CI 0.57–0.94; P=0.016). The median PFS was 66.4 months in the acalabrutinib and 49.6 months in the placebo arm. Of note, 69% of the participants in the placebo arm received BTK inhibitors as a subsequent treatment. According to Prof. Wang, there was also a positive trend in OS, with a hazard ratio of 0.86 (95% CI 0.65–1.13; P=0.27). “If we censor for COVID-related deaths the OS trend was even more positive,” emphasised Prof. Wang (HR 0.75; 95% CI 1.04; P=0.08; see Figure).
Figure: A pre-specified sensitivity analysis of OS with and without COVID-19 deaths [1]
ABR, acalabrutinib plus bendamustine and rituximab; NE, not estimable; OS, overall survival; PBR, placebo plus bendamustine and rituximab.
The safety profiles of the 2 treatment regimens did not differ substantially. Atrial fibrillation occurred in 6.1% of the participants on acalabrutinib and in 4.4% of placebo. Hypertension (12.1% vs 15.8%) and major bleeding (2.4% vs 5.4%) were slightly more common in the placebo arm, whereas infections (78.1% vs 71.0%) were more frequently reported in the acalabrutinib arm.
“The data from ECHO indicate that acalabrutinib plus BR may be a new first-line standard of care for older patients with MCL,” concluded Prof. Wang.
- Wang M, et al. Acalabrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma: results from the phase 3, double-blind, placebo-controlled ECHO trial. LB3439, EHA congress 2024, 13–16 June, Madrid, Spain.
- Phillips TJ, et al. J Clin Oncol. 2023;41(16 suppl):7546.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Clinically meaningful outcomes for mosunetuzumab across follicular lymphoma subgroups Next Article
Updates from the EBMT Lymphoma Working Group: outcomes after allo- and auto-SCT for T-cell lymphoma subtypes »
« Clinically meaningful outcomes for mosunetuzumab across follicular lymphoma subgroups Next Article
Updates from the EBMT Lymphoma Working Group: outcomes after allo- and auto-SCT for T-cell lymphoma subtypes »
Table of Contents: EHA 2024
Featured articles
Meet the Expert: Prof. C. Ola Landgren discusses MRD as a key endpoint in haematological cancer trials
Multiple Myeloma
Isa-VRd proves its value in newly diagnosed MM in the IMROZ trial
PERSEUS: High MRD negativity rates with D-VRd and consolidation therapy and D-R maintenance in MM
Post-intensification data confirm superiority of quadruple therapy in MM
Promising phase 1 results for novel CAR T-cell therapy in MM
DREAMM 8: Belantamab mafodotin offers hope for patients with RRMM
Leukaemia
PhALLCON: Third-generation TKI superior to first-generation TKI in Ph+ ALL
APOLLO: ATRA plus ATO meets expectations in high-risk APL
Excellent phase 3 results for asciminib in chronic myeloid leukaemia
AUGMENT-101: Revumenib trial in KMT2Ar leukaemia stopped early for efficacy
FLAG-Ida plus venetoclax induces high MRD-negativity rates in AML
CD40/CD47 inhibitor shows promise in high-risk MDS and AML
ENHANCE: Magrolimab does not ameliorate health outcomes in high-risk MDS
Can MRD-guided azacitidine treatment improve outcomes in AML and MDS?
Can WGTS replace standard-of-care diagnostics in AML?
Non-malignant Haematology
ENERGIZE: Mitapivat meets primary efficacy endpoint in thalassaemia
Sovleplenib delivers durable responses and QoL improvements in primary ITP
Avatrombopag successful in children with chronic ITP
RUBY: Promising data for first AsCas12a gene-editing therapy in sickle cell disease
Encouraging data for ELA026 to treat secondary haemophagocytic lymphohistiocytosis
Myelofibrosis
Navitoclax plus ruxolitinib leads to spleen volume reductions in myelofibrosis
Is pelabresib plus ruxolitinib the paradigm-shifting combo therapy for myelofibrosis?
Lymphoma
The landscape of TP53 mutations and their prognostic impact in CLL
Can golcadomide plus R-CHOP become the first-line standard of care in high-risk BCL?
High survival rates following atezolizumab consolidation in DLBCL
First results for zanubrutinib plus venetoclax in del(17p)/TP53-mutated CLL/SLL
EPCORE CLL-1: Promising data for epcoritamab in high-risk Richter’s transformation
Updates from the EBMT Lymphoma Working Group: outcomes after allo- and auto-SCT for T-cell lymphoma subtypes
ECHO: Can we expect a novel standard of care in newly diagnosed MCL?
Clinically meaningful outcomes for mosunetuzumab across follicular lymphoma subgroups
Related Articles
February 4, 2022
Novel non-invasive biomarker ctDNA shows value in CNS lymphoma
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com